A New Target and Drug in Bladder and Urinary Tract Cancer Treatment: Erdafitinib for FGFR Mutation

Loriot and colleagues, in NEJM on 25 July 2019, reported a study showing that the fibroblast growth factor receptor 1-4 tyrosine kinase inhibitor erdafitinib, in FGFR mutation-positive urothelial carcinoma (bladder and urinary tract cancer) was effective.
Details of the Study
- The study enrolled patients between May 2015 and March 2018 across 14 countries.
- Patients' tumors carried at least one genetic alteration associated with an FGFR gene: an FGFR3 mutation or an FGFR2 / 3 fusion.
- Patients had unresectable locally advanced or metastatic urothelial cancer.
- Neoadjuvant or adjuvant chemotherapy was followed, at least 12 months later, by disease progression, or patients had a history of progression after at least 1 previous treatment session for metastatic disease.
- Prior immunotherapy use was permitted.
The current study results, for oral erdafitinib at a daily dose of 8 mg, present data on 99 patients. The primary endpoint the study sought to measure was the objective response rate to treatment.
Response Rates
- Median follow-up was 11.2 months.
- An objective treatment response was observed in 40 patients (%40) (complete response % 3).
- Among 22 patients previously treated with immunotherapy, 13 (% 59) achieved a response.
- Median response duration was 5.6 months.
- Median progression-free survival was 5.5 months.,
- The 12-month progression-free survival rate was % 19.
- Median overall survival was 13.8 months, and the 12-month survival rate was % 55.
Adverse Effects
- Severe (grade 3 and higher) adverse effects were observed in % 67 of patients (% 46 were considered treatment-related).
- The most common were hyponatremia (low sodium) (% 11), stomatitis (mouth sores) (% 10) and asthenia (% 7).
- Adverse effects led to treatment discontinuation in 13 patients (% 13), for reasons such as retinal pigment epithelial detachment, hand-foot syndrome, dry mouth and skin or nail events. No treatment-related deaths were reported.
In conclusion, erdafitinib use in previously treated patients with advanced bladder and urinary tract cancer carrying an FGFR genetic alteration was associated with an objective tumor response in % 40 of patients. Treatment-related grade 3 or higher adverse effects were reported in nearly half the patients.
Related Topic:
Sources
Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma.
N Engl J Med, 25 July 2019.
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.